Mikhail Eydelman - 05 Feb 2025 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, GEN COUNSEL & CORP SEC
Signature
Mikhail Eydelman, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
05 Feb 2025
Net transactions value
-$343,319
Form type
4
Filing time
07 Feb 2025, 16:04:12 UTC
Previous filing
07 Jan 2025
Next filing
03 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $107,050 +5,000 +18% $21.41 33,222 05 Feb 2025 Direct
transaction PCVX Common Stock Sale $50,115 -571 -1.7% $87.77 32,651 05 Feb 2025 Direct F1, F2
transaction PCVX Common Stock Sale $56,571 -635 -1.9% $89.09 32,016 05 Feb 2025 Direct F1, F3
transaction PCVX Common Stock Sale $157,860 -1,755 -5.5% $89.95 30,261 05 Feb 2025 Direct F1, F4
transaction PCVX Common Stock Sale $162,437 -1,784 -5.9% $91.05 28,477 05 Feb 2025 Direct F1, F5
transaction PCVX Common Stock Sale $23,386 -255 -0.9% $91.71 28,222 05 Feb 2025 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -5,000 -3.2% $0.000000 149,497 05 Feb 2025 Common Stock 5,000 $21.41 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $87.405 to $88.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $88.52 to $89.385. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $89.53 to $90.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. The shares were sold at prices ranging from $90.66 to $91.585. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 The price reported is a weighted-average price. The shares were sold at prices ranging from $91.69 to $91.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.